Saturday, July 11, 2026

Drug profile · INN

etidocaine hydrochloride

etidocaine hydrochloride (DURANEST) is a sodium channel alpha subunit blocker. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — etidocaine hydrochloride
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

etidocaine hydrochloride (DURANEST) is a sodium channel alpha subunit blocker. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN etidocaine hydrochloride
Brand DURANEST
Mechanism Sodium channel alpha subunit blocker
Target Sodium channel alpha subunit
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Sodium channel alpha subunit blocker

Primary target: Sodium channel alpha subunit

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. carbamazepine Sodium channel alpha subunit blocker
  2. disopyramide phosphate Sodium channel alpha subunit blocker
  3. eslicarbazepine acetate Nervous system (N03)
  4. fosphenytoin sodium Sodium channel alpha subunit blocker
  5. lacosamide Nervous system (N03)
  6. lamotrigine Sodium channel alpha subunit blocker

Frequently asked questions

What is etidocaine hydrochloride?

etidocaine hydrochloride (DURANEST) is a sodium channel alpha subunit blocker. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for etidocaine hydrochloride?

DURANEST is a marketed brand name for etidocaine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of etidocaine hydrochloride?

etidocaine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.